Plant Name: Pinellia ternata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA3; ADORA2A; ADORA1; FFAR1; FFAR4; | |
| GABBR1; | |
| CDA; TDP1; RECQL; BLM; ADK; TK1; HPGD; ALOX15; ALDH1A1; | |
| GAA; ACHE; | |
| GABRR1; | |
| MAPK1; PRKCA; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA5A; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| KDM4E; | |
| MMP12; MMP2; | |
| TLR2; | |
| TP53; STAT6; | |
| KMT2A; | |
| SLC28A3; SLC28A2; SLC6A11; SLC6A1; SLC28A1; | |
| LMNA; RAB9A; FABP3; FABP5; FABP2; FABP4; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PRKCA | Protein kinase C alpha | P17252 | CHEMBL299 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC6A11 | GABA transporter 3 | P48066 | CHEMBL5208 |
| SLC superfamily of solute carriers | SLC6A1 | GABA transporter 1 | P30531 | CHEMBL1903 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family C GPCR) | GABBR1 | GABA-B receptor 1 | Q9UBS5 | CHEMBL2064 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.780E-14 | 4.259E-10 | CA1, CA12, CA2, CA4, CA5A, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.277E-13 | 2.575E-09 | BLM, CA1, CA12, CA2, CA4, CA5A, CA6, CA7, CA9, CDA, KMT2A, MMP12, MMP2, PPARA, PPARD, PPARG, PRKCA, TK1, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.229E-07 | 4.976E-04 | FABP2, FABP3, FABP4, FABP5 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 8.456E-07 | 4.976E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 2.021E-06 | 8.463E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 2.021E-06 | 8.463E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.007E-06 | 1.091E-03 | CA2, CA9, CYP1A2, FABP3, FFAR4, HPGD, PPARA, PPARG, SLC6A1, TLR2, TSHR |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 4.145E-06 | 1.410E-03 | ALOX15, CA2, CYP1A2, FABP4, KMT2A, MAPK1, SLC6A1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.260E-06 | 1.735E-03 | CYP1A2, CYP2A6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 6.823E-06 | 2.153E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 7.559E-06 | 2.255E-03 | ADORA2A, BLM, CA2, CA9, CYP1A2, HPGD, MAPK1, PPARG, SLC6A1, TLR2, TP53 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 8.556E-06 | 2.388E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 8.556E-06 | 2.388E-03 | CDA, MAPK1 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 8.556E-06 | 2.388E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 8.556E-06 | 2.388E-03 | SLC28A2, SLC28A3 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.030E-05 | 2.703E-03 | ADORA1, ADORA2A, PPARA, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.072E-05 | 2.780E-03 | ADORA1, LMNA, MMP2, PPARA, PPARD, TLR2, TP53 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 1.328E-05 | 3.248E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 1.667E-05 | 3.782E-03 | ACHE, ADORA1, ADORA2A, ALDH1A1, CYP3A4, FFAR1, FFAR4, PPARD, PRKCA |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.775E-05 | 3.944E-03 | ADORA1, CA2, CA4, CA9, HPGD, TSHR |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 1.926E-05 | 4.195E-03 | ADORA2A, PPARG, TP53 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 2.562E-05 | 5.213E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.562E-05 | 5.213E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 2.562E-05 | 5.213E-03 | SLC28A1, SLC28A3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.562E-05 | 5.213E-03 | ADORA1, ADORA2A |
| BP | GO:0007610; behavior | GO:0007610; behavior | 2.657E-05 | 5.354E-03 | ADORA2A, GAA, KMT2A, MAPK1, MAPT, PPARA, SLC6A1, TLR2, TP53 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 4.433E-05 | 8.181E-03 | ADORA1, ADORA2A, ADORA3, FFAR1, FFAR4, GABBR1, GABRR1, SLC28A1, SLC28A2, SLC28A3, SLC6A1, SLC6A11, TLR2, TSHR |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 4.547E-05 | 8.321E-03 | FABP3, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.114E-05 | 8.980E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0005332; gamma-aminobutyric acid:sodium symporter activity | 5.114E-05 | 8.980E-03 | SLC6A1, SLC6A11 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 5.399E-05 | 9.265E-03 | ACHE, ADORA2A, BLM, CDA, HPGD, KMT2A, MAPK1, MAPT, PPARG, RAB9A, SMN1, SMN2, STAT6, TK1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.315E-20 | 9.395E-16 | CA1, CA12, CA14, CA2, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.727E-15 | 6.235E-11 | CA1, CA12, CA14, CA2, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.526E-19 | 2.549E-17 | CA12; CA1; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 9.815E-10 | 8.196E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04727 | GABAergic synapse_Homo sapiens_hsa04727 | 5.141E-06 | 2.862E-04 | GABBR1; GABRR1; PRKCA; SLC6A11; SLC6A1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 8.848E-06 | 3.694E-04 | CDA; CYP2A6; TK1; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.141E-05 | 6.495E-04 | GABBR1; ADORA2A; ADORA1; MAPK1; PPARA; TSHR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.333E-05 | 6.495E-04 | ADORA3; ADORA1; MAPK1; PRKCA; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 5.971E-05 | 1.205E-03 | MAPK1; STAT6; PRKCA; TP53; TLR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.526E-05 | 8.412E-04 | CYP2A6; CYP1A2; ALDH1A1; CYP3A4 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.342E-04 | 1.724E-03 | GABBR1; GABRR1; ADORA2A; ADORA3; ADORA1; TSHR |
| hsa05032 | Morphine addiction_Homo sapiens_hsa05032 | 1.317E-04 | 1.724E-03 | GABBR1; GABRR1; ADORA1; PRKCA |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.797E-04 | 3.114E-03 | MMP2; MAPK1; PRKCA; TP53; TLR2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.609E-05 | 1.205E-03 | MAPK1; PPARG; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.609E-05 | 1.205E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.097E-04 | 7.996E-03 | MMP2; MAPK1; PRKCA; PPARG; TP53; PPARD |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.466E-04 | 5.369E-03 | MAPK1; PRKCA; TP53 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.167E-04 | 2.584E-03 | MMP2; MAPK1; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 8.458E-04 | 7.847E-03 | MAPK1; PRKCA; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.466E-04 | 5.369E-03 | FABP4; ADORA1; TSHR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.006E-03 | 8.403E-03 | CYP2A6; CYP1A2; CYP3A4 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.728E-03 | 1.255E-02 | HPGD; KMT2A; PPARG; TP53 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.185E-03 | 9.424E-03 | CYP2A6; CYP1A2; CYP3A4 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.001E-03 | 1.790E-02 | MMP2; MAPK1; PRKCA |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.232E-03 | 1.491E-02 | MMP2; MAPK1; PRKCA |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.836E-03 | 1.790E-02 | GABBR1; MMP2; MAPK1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.916E-03 | 2.235E-02 | ACHE; MAPK1; PRKCA |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.657E-03 | 1.255E-02 | CYP2A6; CYP1A2; CYP3A4 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 3.001E-03 | 1.790E-02 | GABRR1; MAPK1; PRKCA |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.015E-03 | 2.235E-02 | ALOX15; MAPK1; PRKCA |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 6.006E-03 | 2.950E-02 | MAPK1; PRKCA; MAPT; TP53 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.646E-03 | 2.503E-02 | MAPK1; PRKCA; TP53 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 4.869E-03 | 2.541E-02 | ADORA2A; MAPK1; PRKCA |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 7.968E-03 | 3.412E-02 | CDA; CYP2A6; GAA; CYP1A2; ALOX15; ALDH1A1; ADK; TK1; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.455E-03 | 3.365E-02 | LMNA; MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.475E-03 | 3.089E-02 | MAPK1; PPARA; TP53 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.885E-03 | 3.194E-02 | RAB9A; TP53; TLR2 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 7.751E-03 | 3.406E-02 | PRKCA; TP53; PPARD |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.203E-02 | 4.673E-02 | ADORA3; ADORA1; MAPK1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.152E-02 | 4.673E-02 | MAPK1; PPARD |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.658E-03 | 4.032E-02 | MAPK1; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.271E-02 | 4.716E-02 | MAPK1; PRKCA |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.311E-02 | 4.761E-02 | MAPK1; PRKCA |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.271E-02 | 4.716E-02 | MAPK1; PRKCA |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 5.527E-03 | 2.797E-02 | MAPK1; PRKCA |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.353E-02 | 4.806E-02 | MAPK1; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.191E-02 | 4.673E-02 | CYP1A2; CYP3A4 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.943E-03 | 1.352E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 7.937E-05 | 1.205E-03 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TK1 |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TK1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; MAPK1; TLR2; MMP2; TK1; CDA |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Myeloma | C90 | SLC6A1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; SLC6A1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; CA1; CA1; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; MMP12; MMP12 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD; MMP12 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADORA1; MMP12 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; MMP2; TK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1; ACHE |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; PPARG |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; TP53; CA1; CA9; MAPK1; TLR2; MMP2; TK1; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |